Hook and thesis
Aveanna Healthcare (AVAH) has moved from recovery to expansion: recent quarters show strong top-line growth, EBITDA expansion and a material step toward delevering after the company completed a strategic pediatric add-on. The market has rewarded this execution with a run to a $14 52-week high, but valuations still look reasonable relative to the growth profile and cash generation. We view AVAH as a buy on a 180 trading day time horizon.
Our trade thesis: buy AVAH at $13.32 with a target of $18.00 and a stop at $11.50. The case rests on three pillars - recurring, high-acuity home-care demand that supports predictable revenue; margin and adjusted EBITDA leverage that has driven rapid profitability gains; and improving free cash flow plus a path to reduce net debt. Those elements together justify multiple expansion from current EV/EBITDA and P/E levels if execution continues.
What Aveanna does and why investors should care
Aveanna provides home-based care through three segments: Private Duty Services (PDS), Home Health & Hospice (HHH), and Medical Solutions (MS). The business benefits from long-duration relationships, regulated reimbursement that supports steady revenue streams, and specialized service lines such as pediatric home care and respiratory/enteral nutrition supplies that command higher stickiness and margins.
The market should care for two reasons. First, demographic and clinical trends - aging populations and increased preference for home-based care - favor scale players that can deliver integrated services. Second, Aveanna is visibly improving unit economics: management has raised full-year 2026 guidance after closing the Family First Homecare acquisition (06/02/2026) and the company is converting growing EBITDA into free cash flow, improving the balance sheet over time.
Evidence and numbers that support the bullish case
| Metric | Value |
|---|---|
| Market cap | $2.91B |
| Price / Earnings | ~10.6 |
| EV / EBITDA | ~14.6 |
| Price / Sales | ~1.12 |
| Free cash flow (trailing) | $158.4M |
| 2025 revenue | $2.43B (up 20.2% y/y) |
| 2026 guidance (revised) | $2.63 - $2.65B revenue; Adjusted EBITDA $338 - $342M |
| Acquisition - Family First | $175.5M cash purchase; adds $70M revenue and $10M EBITDA |
Concrete takeaways: 2025 revenue accelerated to $2.43B (+20.2% y/y) and adjusted EBITDA expanded strongly (management cited a 75% EBITDA surge in recent commentary). The Family First transaction closed on 06/02/2026 and management raised 2026 revenue guidance to $2.63-$2.65B and adjusted EBITDA to $338-$342M, with Family First contributing about $70M of revenue and $10M of EBITDA. Trailing free cash flow of $158M provides tangible capacity to pay down debt or fund accretive tuck-ins.
Valuation framing
On absolute metrics AVAH trades at a P/E around 10.6 and EV/EBITDA near 14.6. For a company growing revenue at ~20% and improving margins, an EV/EBITDA in the mid-teens is not outlandish, especially given the recurring nature of its revenues and the scale benefits in home-health. Price/sales is moderate at ~1.12, reflecting that scale and recent margin expansion.
Historically, health services businesses with steady reimbursement and improving cash conversion can carry higher multiples. If Aveanna hits the midpoint of its 2026 adjusted EBITDA guidance (~$340M) and continues to convert more EBITDA into free cash flow while trimming leverage, a re-rating toward a 16-18x EV/EBITDA (or modestly higher P/E) becomes plausible - the math supports the target in our trade plan.
Catalysts (what will drive the trade)
- Integration and margin accretion from Family First (closed 06/02/2026) - expected to add $10M EBITDA and lift pediatric service density across 27 locations.
- Continued quarterly beats on revenue and adjusted EBITDA; management has already been raising guidance.
- Deleveraging - conversion of free cash flow into debt paydown, improving debt-to-equity and lowering interest costs.
- Operational certifications and program wins (example: CHAP disease program certification for Heartways announced 02/11/2026) that can increase referrals and payer confidence.
- Further accretive tuck-in M&A that increases scale and adds specialized, higher-margin lines.
Trade plan (actionable)
We recommend a long trade with the following parameters:
- Entry price: $13.32
- Target price: $18.00
- Stop loss: $11.50
- Horizon: long term (180 trading days) - rationale: the thesis depends on continued quarterly cadence of revenue and EBITDA beats, visible progress on debt reduction and successful integration of Family First, all of which unfold over several quarters.
Position sizing: given execution and balance-sheet risks, size the position to reflect a medium risk tolerance - we view this as a medium-risk trade. The stop at $11.50 protects capital should momentum reverse or guidance disappoint; the $18 target reflects a combination of multiple expansion and mid-single-digit organic growth plus accretion from the recent acquisition.
Why this entry and target?
$13.32 sits inside the recent trading range (shares hit a 52-week high at $14 on 08/27/2026). The target of $18 assumes a modest multiple re-rate and continued EBITDA expansion: if adjusted EBITDA approaches $340M and EV/EBITDA expands modestly from ~14.6x toward the high-teens, equity value supports a mid-teens to high-teens price - the $18 target is reachable if the fundamentals continue to improve over the next several quarters.
Risks and counterarguments
- Leverage remains elevated. Reported debt-to-equity is high (~5.08). If free cash flow weakens or integration costs rise, deleveraging may stall and the stock could re-rate lower.
- Reimbursement and regulatory risk. Home-health and specialty pediatric services are sensitive to reimbursement changes and payer mix shifts. Adverse regulatory moves or payer contract pressure would hurt margins quickly.
- Integration risk and M&A execution. The Family First acquisition is accretive on paper ($70M rev / $10M EBITDA) but integration execution could absorb cash and management attention; unexpected costs would pressure results.
- Momentum/valuation pullback. Technical indicators show a high RSI (~71) and the stock has rallied sharply; a near-term pullback or profit-taking (including selling by large holders) could create volatility.
- Macro or capital markets shock. Higher rates or a risk-off environment could compress multiples across the sector, reversing the multiple expansion in our thesis.
Counterargument: One reasonable counterargument is that the recent multiple expansion already prices in the best execution scenario. If the market believes much of the upside is now baked in after the run to a 52-week high and continued insider/major-holder selling occurs, the stock could grind sideways — in that case the prudent move is to wait for a pullback toward the low $11s or the 10-day/20-day moving averages before layering in.
Monitoring and what would change my mind
Watch these indicators closely:
- Quarterly results vs. guidance: misses to revenue or adjusted EBITDA would invalidate portions of the thesis.
- Free cash flow and net debt trajectory: a failure to convert EBITDA into cash would be a red flag.
- Integration progress on Family First: material churn or unexpected integration costs would reduce the probability of hitting the target.
- Short interest and technical momentum: a sustained pick-up in short days-to-cover or RSI failure under 50 on heavy volume could signal a momentum reversal.
What would change my mind to a more bullish stance: faster-than-expected deleveraging (meaningful debt paydown or refinancing at lower rates), sustained margin expansion that pushes adjusted EBITDA meaningfully above the guidance midpoint, or evidence of accelerated organic demand across new markets.
What would change my mind to a bearish stance: consecutive quarters of revenue/EBITDA misses, a sudden deterioration in cash flows, or regulatory/payer actions that compress reimbursement rates materially.
Conclusion
Aveanna's combination of strong organic revenue growth, accretive M&A, improving adjusted EBITDA and meaningful free cash flow make the stock an attractive long trade in our view. At a market cap of roughly $2.9B, P/E near 10.6 and EV/EBITDA ~14.6, the valuation still allows room for multiple expansion if management continues to deliver. Our actionable trade: buy at $13.32, stop at $11.50, target $18.00, with a long-term horizon of 180 trading days to allow the operational and deleveraging thesis to play out.
Trade plan summary: Long AVAH at $13.32, target $18.00, stop $11.50. Horizon - long term (180 trading days).